Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03470545 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Phase 3 study, sponsored by MyoKardia.
- Completed
- Registry status
- Phase 3
- Development phase
- 251
- Enrollment target
NCT03470545 is a Phase 3 study that has completed, run by MyoKardia. The registered enrollment target is 251 participants.
The verdict
NCT03470545, a Phase 3 study, has completed, sponsored by MyoKardia.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 251 participants
- Enrollment target
Study Summary
This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will be randomized to receive placebo or mavacamten.
Interventions
- DRUG Placebo
- DRUG mavacamten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2020-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03470545
The ClinicalTrials.gov registry entry for NCT03470545 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MyoKardia, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03470545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03470545 about?
NCT03470545 is a clinical study titled "Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy". This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will be randomized to receive placebo or mavacamten.
What is the current status of trial NCT03470545?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 251 participants. The study started on 2018-05-29. Estimated completion is 2020-05-06.
What interventions are being tested in trial NCT03470545?
The interventions under investigation include: Placebo (DRUG), mavacamten (DRUG).
Who is sponsoring clinical trial NCT03470545?
This trial is sponsored by MyoKardia, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.